Fabrice Branle
Novartis (Switzerland) · 91 works · 3,190 citations · h-index 17
Top works
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
- A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
- Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis
- ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
- Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy
- ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).
- Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)
- Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
- A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma
- Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
- The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature
- MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
- Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma
- A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors
- Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium
- Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain
- A meta-analysis of the role of etoposide (VP16) and cisplatin (CDDP) in small cell lung cancer (SCLC) with a methodology assessment
- A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo) astrocytoma: An interim analysis of toxicity